These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 3068163)
1. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil. Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163 [TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787 [TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Nikkilä EA; Ylikahri R; Huttunen JK Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608 [TBL] [Abstract][Full Text] [Related]
4. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Saku K; Sasaki J; Arakawa K Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372 [TBL] [Abstract][Full Text] [Related]
5. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia. Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951 [TBL] [Abstract][Full Text] [Related]
6. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Olsson AG; Rössner S; Walldius G; Carlson LA Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):28-31. PubMed ID: 190607 [TBL] [Abstract][Full Text] [Related]
7. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR Artery; 1985; 12(6):363-81. PubMed ID: 4051756 [TBL] [Abstract][Full Text] [Related]
8. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558 [TBL] [Abstract][Full Text] [Related]
9. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394 [TBL] [Abstract][Full Text] [Related]
10. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694 [TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers. Koskinen P; Kovanen PT; Tuomilehto J; Manninen V Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934 [TBL] [Abstract][Full Text] [Related]
13. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals]. Hutt V; Klör HU; Wechsler JG; Ditschuneit H J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054 [TBL] [Abstract][Full Text] [Related]
14. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797 [TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595 [TBL] [Abstract][Full Text] [Related]
17. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV]. Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145 [TBL] [Abstract][Full Text] [Related]
18. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia]. Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study. Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217 [TBL] [Abstract][Full Text] [Related]
20. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. II. Results of the treatment in relation to the type of hyperlipoproteinemia]. Sznajd J; Idzior-Waluś B; Korzus G; Zabiński J; Hebda A; Markiewicz M Przegl Lek; 1990; 47(10):711-4. PubMed ID: 2089450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]